CTOs on the Move

Bioanalytical Systems

www.basinc.com

 
BASi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. We provide world-class research to the global pharmaceutical industry. Our services include Preclinical Toxicology, Early In Vivo PK, Bioanalysis and a full range of pharmaceutical analysis services. BASi also manufactures innovative scientific instruments including the Culex® Automated In Vivo Sampling System which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. We are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.basinc.com
  • 2701 Kent Ave
    West Lafayette, IN USA 47906
  • Phone: 765.463.4527

Executives

Name Title Contact Details

Similar Companies

Liberty HealthShare

Liberty HealthShare is a group of self pay patients who freely share each others` medical expenses on a voluntary, cooperative basis. Liberty HealthShare is not insurance. We simply unite like minded Americans to share medical expenses together. Our mission is to make the Christian tradition of healthcare sharing available and affordable to all.

Pro-Dex

Pro-Dex, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Physician Health Partners

Physician Health Partners is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

Chrysallis Center

Chrysallis Center is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.